The effects of favipiravir on hematological parameters of covıd-19 patients
Open Access
- 1 January 2020
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (suppl 2), 65-70
- https://doi.org/10.1590/1806-9282.66.s2.65
Abstract
INTRODUCTION: This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections. METHODS: Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed. Hematologic parameters were analyzed before and after the treatment. RESULTS: The mean age of the patients receiving treatment with favipiravir was 63.7 +/- 12.3 years. Nasopharyngeal swab positivity was detected in 67.7%. The most common comorbid conditions detected in patients were hypertension in 25 cases (40.3%) and diabetes in 16 cases (25.8%). In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected; the mean RBC was found to have decreased from 4.33 +/- 0.58 M/uL to 4.16 +/- 0.54 M/uL (p:0.003); the median hemoglobin level was found to have decreased from 12.3 g/dl to 11.9 g/dl (p:0.041); the hematocrit level decreased from 38.1% +/- 4.8 to 36.9% +/- 4.2 (p:0.026); the median neutrophil count decreased from 4.57 K/uL to 3.85 K/uL (p:0.001); the mean lymphocyte count increased from 1.22 +/- 0.53 K/uL to 1.84 +/- 1.79 K/uL (p:0.000); and the mean platelet count increased from 244.1 +/- 85.1 K/uL to 281.9 +/- 103.3 K/uL (p:0.005). CONCLUSION: We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters.Keywords
This publication has 18 references indexed in Scilit:
- Use of Favipiravir to Treat Lassa Virus Infection in MacaquesEmerging Infectious Diseases, 2018
- Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse modelAntiviral Research, 2018
- Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virusAntiviral Research, 2018
- Hematologic abnormalities and associated factors among HIV infected children pre- and post-antiretroviral treatment, North West EthiopiaJournal of Blood Medicine, 2017
- Favipiravir (T-705) Inhibits Junín Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic FeverPLoS Neglected Tropical Diseases, 2013
- Drug-Induced Hematologic SyndromesAdvances in Hematology, 2009
- T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infectionsAntiviral Research, 2009
- Lamivudine-induced red cell aplasiaJournal of Medical Microbiology, 2008
- Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral TherapyThe American Journal of Gastroenterology, 2007
- Ribavirin-Induced Pure Red-Cell Aplasia during Treatment of Chronic Hepatitis CThe New England Journal of Medicine, 2004